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Abstract: Glioblastoma (GBM), the most common and aggressive primary brain tumor in adults,
remains one of the least treatable cancers. Current standard of care—combining surgical resection,
radiation, and alkylating chemotherapy—results in a median survival of only 15 months. Despite
decades of investment and research into the development of new therapies, most candidate
anti-glioma compounds fail to translate into effective treatments in clinical trials. One key issue
underlying this failure of therapies that work in pre-clinical models to generate meaningful
improvement in human patients is the profound mismatch between drug discovery systems—cell
cultures and mouse models—and the actual tumors they are supposed to imitate. Indeed, current
strategies that evaluate the effects of novel treatments on GBM cells in vitro fail to account for a
wide range of factors known to influence tumor growth. These include secreted factors, the brain’s
unique extracellular matrix, circulatory structures, the presence of non-tumor brain cells, and nutrient
sources available for tumor metabolism. While mouse models provide a more realistic testing ground
for potential therapies, they still fail to account for the full complexity of tumor-microenvironment
interactions, as well as the role of the immune system. Based on the limitations of current models,
researchers have begun to develop and implement novel culture systems that better recapitulate the
complex reality of brain tumors growing in situ. A rise in the use of patient derived cells, creative
combinations of added growth factors and supplements, may provide a more effective proving
ground for the development of novel therapies. This review will summarize and analyze these
exciting developments in 3D culturing systems. Special attention will be paid to how they enhance
the design and identification of compounds that increase the efficacy of radiotherapy, a bedrock of
GBM treatment.
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1. Introduction
In glioblastoma (GBM), we have seen the disastrous result of insufficiently realistic drug screening
and testing systems. From cilengitide to target therapies, drugs developed using contemporary
pre-clinical systems have roundly failed to predict clinical efficacy. We believe that a large part of the
blame for these failures should be laid at the feet of our overly simplified in vitro culture and murine
systems. At every level, the defining characteristic of GBM is complexity. From genetic anomalies
and epigenetic dysregulation [1,2] to cellular plasticity [3], immunosuppression [4], and metabolic
adaptability [5–7], GBM exhibit a wide diversity of phenotypes and possess a remarkable toolbox for
colonizing the brain and resisting current treatment regimens. The failure of current radiotherapy
paradigms to provide long-term tumor control in GBM has been linked to all these factors [8].
In addition to these tumor factors, GBM remains intractable because of its ability to interact with
its environment, including healthy astrocytes and blood vessels. The blood-brain-barrier further
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complicates therapeutic design. The challenge of pre-clinical drug development is to create culture
systems and animal models that faithfully recapitulate these complex behaviors and systems, thereby
enabling researchers to identify compounds that effectively translate success targeting cancer cells
in vitro models to meaningful improvement for patients. This review will analyze the limitations
of current GBM drug development models and summarize and discuss novel culture systems
under development.
2. Limits of Current Pre-Clinical Systems
In order to discuss the potential of novel culture systems to more effectively ascertain the clinical
potential of candidate compounds, we must first discuss the current state of GBM culture and murine
models. Further, we must delineate how the immense complexity of brain tumor genetics and the vast
influence of the brain microenvironment limit their utility. Figure 1 illustrates the current mismatch
between tumors growing in patients and present culture protocols.
Figure 1. Schematic comparison of tumor microenvironment and current culture systems. (A) The
brain microenvironment provides a multitude of non-tumor cell types, including neurons, astrocytes,
microglia, and endothelial cells. These populations are present in the tumor environment and have
been shown to influence the progression of GBM tumors, as well as abet their ability to resist current
standard of care therapies, including radiation. In addition, tumor cells in the brain grow in a complex
3D structure entangled with a brain-specific extra-cellular matrix (ECM). They also exhibit a marked
amount of intratumoral heterogeneity, with a variety of subpopulations within each tumor. Finally,
the tumor microenvironment varies widely across different anatomic locations, with differences in
oxygen and nutrient availability; this range of milieus contributes to the intratumoral heterogeneity
of GBM. (B) In contrast, current culture systems are over-simplified and introduce variables not
encountered in the brain. Oxygen concentrations are held constant at 20% by most incubators, while
media contains an elevated amount of glucose. Plastic flasks introduce an unnaturally stiff surface,
which GBM cells are known to react to. Further, coating flask with matrigel, while better than culturing
directly on plastic, exposes tumor cells to elevated levels of collagen and laminin. Mono-cultures mean
that in vitro experiment fail to account for non-tumor cells contributions to the microenvironment.
2.1. Current Practices for Pre-Clinical GBM Modeling
At present, the gold standard of GBM in vitro culture systems relies on the use of patient derived
(PD) cells. Human immortalized glioma cells, such as U87 and U251, have fallen out of favor due to
lack of similarity to actual GBM tumor cells and controversy regarding their origins [9]. In their place,
a variety of PD lines have been developed. These cells are derived from the tumor tissue removed
during surgical resection, which is processed to generate cell lines that can be passaged through the
flanks of immunodefficient mice and cultured as monolayers or in suspension. A wide number of
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these cell lines exist, usually created at academic institutions and then shared through collaborations
across the neuro-oncology research network.
A range of culture conditions are used to propagate these cells once they are growing in vitro.
The different choices of media and additives were recently reviewed [10]. A survey of the literature
demonstrated that the majority of labs currently employ Dulbecco’s Modified Eagle Medium (DMEM)
on its own or in combination with F12, a nutrient mixture (SigmaAldrich, St Louis, MO, USA). This
media contains a mix of glucose, amino acids, inorganic salts, and vitamins. In addition, many
groups now add growth factors to their media, most commonly epidermial growth factor (EGF)
and/or basic fibroblast growth factor (bFGF). The addition of these growth factors has been shown
to promote maintenance of gene expression characteristics observed in human patient samples and
proliferation [11]. Finally, the use of supplements like N2 and B27 is continuing to rise in GBM culture.
The main component of N2 is putrescine, a diamine generated in the decomposition of amino acids
(ThermoFisher, Waltham, MA, USA). The exact composition of B27 is proprietary, but it contains a
variety of lipid compounds, including linoleic acid, corticosterone, and progesterone (ThermoFisher).
As we will see, the composition of media can have a profound effect on the phenotype of GBM cells,
making culture conditions a key factor limiting the efficacy of current models.
Cells grown as monolayers undergo profound phenotypical changes and have been reported to
exhibit markedly different responses to cytotoxic treatments than those observed in patients [12–14].
In the context of radiation therapy, 3D culture of lung and head & neck cancer cells embedded in
laminin-rich extracellular matrix (ECM) has been shown to promote radiation resistance compared to
2D culture by chromatin condensation, facilitating repair of DNA double strand breaks (DSB) [12,15,16].
Colorectal cancer cell lines cultured in similar laminin-rich ECM 3D conditions also exhibited changes
in cellular morphology, phenotype and gene expression and were resistant to treatment with epidermal
growth factor receptor (EGFR) inhibitors compared to cells cultured in 2D conditions [13,17]. In the
context of GBM, cells exhibited differential radiosensitisation to EGFR and VEGF inhibitors in 2D and
3D systems [18]. These observations provide a potential explanation for the frequent failure of results
derived from conventional 2D cell culture systems to predict clinical efficacy [19,20], a phenomenon
that leads to inappropriate and excessive use of animal testing.
2.2. Tumor Intrinsic Factors
Each GBM tumor is highly unique in terms of genetic etiology and gene expression profile.
In addition, we know from decades of research that GBM is a highly dynamic tumor type, rapidly
adapting to changes in its surroundings. As such, any effort to model this cancer in the dish must rely on
careful consideration of a number of variables when initiating cultures and selecting culture conditions.
2.2.1. Inter and Intratumoral Genetic Heterogeneity
Genetic variation is a hallmark of GBM. A landmark paper, examining over 400 primary
patient samples, identified four subtypes of tumors based on their genomic characteristics.
Many of the mutations that defined the groups occurred in receptor tyrosine kinases, including
epidermal growth factor receptor (EGFR) and platelet derived growth factor receptor (PDGFR) [2].
Subsequent research has reduced the four subtypes of tumor to three groups—classical, proneural,
and mesenchymal—although the clinical relevance of these classifications remains uncertain. Further
complicating the matter, recent reports utilizing advances in single cell RNA sequencing have
demonstrated that many patients’ tumors actually contain cells of all three subtypes [21]. This
intratumoral heterogeneity includes the key growth factors, with reports of mosaic amplification of
several receptor tyrosine kinases [22], as well as subpopulations within tumors expressing a multitude
of variants for a single kinase [1]. This diversity also involves the presence of a subpopulation of tumor
cells termed glioma initiating cells or glioma stem-like cells (GSCs). GSCs take their name from the
fact that they display many of the key features of healthy neural stem cells, including the ability to
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self-renew, the capacity to generate progeny of a variety of different cell types, and expression of key
stem cell related genes [23,24]
This genetic heterogeneity complicates the process of modeling GBM in vitro. First, each
patient-derived (PD) cell line represents only one of the multitudes of genetic permutations that
can underlie a GBM tumor. For example, a panel of PD GBM lines originally developed by a group
at the Mayo Clinic varied greatly across each sample in terms of well-established GBM mutations,
including epidermal growth factor receptor (EGFR), phosphatase and tensin homologue (PTEN), p53,
and platelet derived growth factor receptors A (PDGFRA) [25]. While the status of these mutations
in each tumor were maintained in murine intracranial xenografts, the fact remains that selecting a
PD cell line inherently for experiments fundamentally biases the experiment. A similar set of cell
lines, with a range of genetic and phenotypic profiles, has been generated by a group at the University
of Cambridge [26]. In light of this bias, it is critical that a variety of cell lines be utilized for all
experiments, in order to guard against biased results. These panels will also provide critical insight
into potential predictive biomarkers, as efficacy in cell lines only bearing certain specific mutations
would point towards potential use in select patient populations. Second, the process of deriving a cell
line from patient tumors is inherently a selection process. Since the first attempts to culture brain tumor
cells from surgical biopsies in 1929, only certain samples have been capable of growing in vitro [27].
The specific clones of each tumor that survive and grow in culture will automatically skew the results
of assays, as these clones represent only a certain subpopulation of the tumor. In order to compensate
for this issue of intertumoral heterogeneity, labs must perform all their pre-clinical assays and animal
modeling using multiple cell lines of different subtypes. This factor inherently multiples the resources
and time required to explore new therapies for GBM.
In terms of intratumoral diversity, the process of culturing GBM cells remains incredibly
complicated. Evidence increasingly shows that different subpopulations of tumor cells have a unique
role to play in tumor maintenance and progression. For example, it has recently been shown that
differentiated GBM cells communicate bi-directionally with GSCs, promoting GBM progression [28].
The selection process inherent in deriving cells from patient samples carries an extremely high risk of
losing certain tumor subpopulations, and subsequently the loss of subpopulation interactions critical
for tumor behavior. Current culture techniques often promote homogeneity in cells, thereby limiting
their utility. As we shall discuss, some novel in vitro techniques have improved capacities for the
maintenance of a heterogeneous cell mixture.
2.2.2. Cellular Plasticity
Further complicating the generation of representative tumor cultures, GBM cells have
demonstrated a profound ability to adapt their phenotypes to their surroundings. Rather than existing
as a stable population, GBM cells exist in a state of dynamic equilibrium [3]. Termed cellular plasticity,
this process means that brain tumors are a moving target, capable of acquiring multiple different
phenotypes. Microenvironmental cues from acidity and hypoxia, as well as the stress caused by
chemotherapy and radiation, can alter the gene expression and functional state of GBM cells, including
induction of the GSC state [3,29–35]. Research continues to identify novel environmental activators of
cellular plasticity. A recent report highlighted extracellular vesicles secreted from apoptotic GBM cells
transfer splicing factors to surviving neighbors, altering recipient cell transcription and shifting them
to a more aggressive phenotype [36].
The sensitivity of GBM cells to their surroundings has implications for the process of generating
useful in vitro models of brain tumors, because even subtle changes in culture conditions may have
a high degree of influence on phenotype. For example, the addition of fetal bovine serum (FBS),
a traditional additive to media for cell cultures, has been shown to drastically alter the phenotype of
patient derived GBM cells. Specifically, the presence of serum led to the loss of GSC subpopulation
and the outgrowth of cells with novel genetic and functional characteristic that did not match the
initially isolated sample [11]. This study provided the impetus for the adoption of the serum-free,
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growth factor containing cultures in use today. However, it has since been shown that slight changes
in the concentration of various additive growth factors can alter cell behavior and drug sensitivity
(recently reviewed [10]). In addition, the act of passaging cells itself has been shown to activate cellular
plasticity, altering the gene expression and phenotype of patient derived GBM cells, including drug
sensitivity [37]. For cell lines that are passaged through mouse flanks or brain, it has been shown that
these processes cause mouse specific changes in tumor phenotype and gene expression, again leading
to inconsistent sensitivity to drugs [38]. Clearly, the adaptability of GBM cells to their environment
means that great care must be taken to maximize consistency within labs and across research groups.
2.3. Microenvironmental Factors
The brain represents one of the most complicated organ systems in the human body. Its function
relies heavily on the cultivation of a microenvironment that promotes effective communication
between and among astrocytes and neurons. As a result, the brain utilizes an outsized amount
of glucose to enable the energetically expensive processes of cognition [39]. In addition, the cellular
microenvironment is more regulated than in the periphery, with blood vessels and transport of
nutrients into the brain being tightly controlled by astrocytes and other cellular and non-cellular
components [40]. Termed the blood brain barrier (BBB), these structures enable the creation of a highly
specific molecular milieu within which GBM must survive and proliferate, and in turn complicates
GBM therapy (recently reviewed [41]). From nutrients to growth factors, the brain is a unique place for
cancer to occupy (expertly reviewed [42]). Many of these factors, however, are not currently accounted
for in culture systems.
2.3.1. Brain Extracellular Matrix
One of the unique features of the brain is the composition of the extracellular matrix (ECM).
While the ECM of many tissues contains large amounts of collagen and laminin, the brain’s ECM is
relatively low in these fibrous ECM component, mainly found surrounding blood vessels, and more
defined by the presence of large amounts of specific proteoglycans and glycoproteins [43]. It has
been known for decades that the brain contains elevated levels of hyaluronic acid and heparin sulfate
proteoglycans [44]. Thus, culture coating techniques borrowed from research on other organs or tumor
types will likely fail to recapitulate the composition of the brain microenvironment. Experimental
evidence confirms that differences in the ECM are anything but trivial. GBM cells are sensitive to the
stiffness of their surroundings, responding to different environments with changes in invasive capacity
and proliferation rates [45]. An analysis of patient samples confirms that the stiffness plays a key role
in GBM, with ECM stiffness positively correlated with tumor aggressiveness [46]. Thus, the selection
of plastic and coatings for cultures represent a key question in designing cultures for GBM. Further
complicating the process of modeling GBM, the ECM surrounding tumors varies widely depending
on the portion of the tumor examined and influences progression [47]. Current culture techniques fail
to account for either the unique ECM of the brain or its heterogeneity across tumor compartments.
Coated flask will have the same coating over the full surface area, thereby creating a homogenous
environment. In light of the connection between microenvironmental factors and cellular phenotype,
these homogeneous surroundings may affect the behavior of GBM cells and push them towards an
artificial state in vitro, limiting the utility of current models for pre-clinical drug development.
2.3.2. Regional Differences in the Tumor Microenvironment
These differences across tumor compartments extend beyond the composition of the ECM. Several
different anatomic areas, characterized by unique environmental components and the presence of
distinct subpopulations of tumor cells, have been described, including the necrotic core, perinecrotic
zone, cellular tumor, leading edge, infiltrating tumor, pseudopalisading cells, hyperplastic blood
vessels, and microvessel proliferating cells. Indeed, in situ hybridization studies from the Allen
Institute illustrated the intense heterogeneity of gene expression across individual tumors [48].These
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areas are known to be formed of, and indeed to promote the formation of, specific subpopulations of
cells. Critically, GSC preferentially occupy the perivascular niche and the perinectrotic zone [49,50].
Vascularization of tumors is another key factor in microenvironmental heterogeneity. GBM exhibit
frequent and severe hypoxia and secrete high levels of pro-angiongenic factors, leading to the formation
of a large network of irregular blood vessles [51,52]. These factors, combined with the explosive growth
rates of many GBM, result in variable oxygen availability throughout the tumor [53,54]. Given that
hypoxia has been well established to alter the gene expression and phenotype of GBM cells, these
regional differences contribute to the heterogeneous nature of brain tumors [29,35,55,56].
Current cell culture techniques fail to account for these regional differences in the surroundings
encountered by GBM tumors. As most cultures are monolayers in petri dishes or culture flasks,
the availability of oxygen and nutrients is uniform based on simple diffusion. While hypoxic chambers
have been used to examine the effects of hypoxia on GBM cells [34,35,55], these experiments alter the
conditions of the entire population, rather than recapitulating the wide range of oxygen availabilities
across the tumor microenvironment.
2.3.3. Nutrient Availability and Metabolism
Since the identification of the Warburg Effect, the metabolic behavior of tumors has been of intense
interest to cancer researchers. Specifically in the case of GBM, this topic has gained more attention in
recent years because of its connection to tumor heterogeneity. Metabolomic and proteomic analysis
of 17 PD glioma stem cells indicated that, as with genetic anomalies, GBM exhibit a heterogeneous
range of metabolic phenotypes, which appear to cluster into two groups—a proneural-like group
characterized by neurotransmitter metabolites and a mesenchymal-like group, characterized by
elevated lipid metabolism [7]. In addition, metabolic behavior in GBM has been linked to tumor
growth, cell signaling, and epigenetic regulation of gene expression [57–60]. The role of metabolism
in GBM further complicates efforts to faithfully model this tumor in vitro. As mentioned previously,
the majority of GBM culturing occurs in DMEM media, which contains approximately 25 mM glucose
(manufacturer’s website). In contrast, normal brain extracellular glucose levels are approximately
4.5 mM [61]. It is understandable that media contains higher levels of glucose in order to ensure
sufficient energy supply in the absence of blood supply. However, these initial high levels may alter
the state of cells and influence cellular response in assays and drug screens. Indeed, a recent report
showed that glucose concentration alters the activity of many key kinases in GBM cells; sensitivity to
inhibitors with therapeutic potential varied widely based on glucose availability [62]. The importance
of understanding the dynamic nature of the tumor microenvironment is discussed in detail below.
In addition, current nutrient supplements (F12, B27, and N2) provide only a selection of lipid and fatty
acid compounds. Many studies have shown that nutrient availability and use exert great influence over
GBM cells [39,63]. This means that media composition, with elevated glucose and limited diversity of
other energy sources, is likely to alter GBM phenotype and generate in vitro models that do not reflect
actual tumors.
2.3.4. Non-Tumor Cells: Secreted Factors and Contact-Mediated Interactions
Another key factor influencing the behavior of GBM is the presence of neighboring non-tumor
cells, which can modulate tumor cells and the microenvironmental milieu via both the secretion
of factors and direct contact. These cell types include astrocytes, neurons, endothelial cells,
and brain-resident microglia, as well as peripheral immune cells that have entered tumors (though the
exact extent of peripheral immune involvement remains a topic of much debate).
Astrocytes, the most abundant cells in the human brain, play a key role in supporting neurons
and sculpting the microenvironment under normal conditions (reviewed [64]). Astrocyte co-culture
experiments reveal that these same processes may participate in the onset and progression of
glioblastoma. For example, a recent report demonstrated that GBM tumor cells are highly dependent
on cholesterol secreted by nearby astrocytes for their survival [65]. Astrocytes have also been shown to
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promote invasion by GSCs via the secretion of cytokines [66]. Co-culture experiments have provided
more insight into the role of healthy astrocytes in influencing GBM progression. GBM cells grown in
mixed culture with astrocytes were less sensitive to radiation via chemokine release and activation of
STAT3 [67]. Reactive gliosis, a process by which astrocytes become activated following brain injury
and begin to secrete a variety of factors, including chemokines, is well-established in the peri-tumoral
area [68]. It has been demonstrated that this reactive gliosis increases tumor proliferation and invasion
in mouse models [69]. In addition to secreted factors, a number of studies have shown that astrocytes
physically interconnect with brain metastases and promote tumor colonization [70]. We suspect it is
only a matter of time before similar evidence emerges linking GBM growth to contact with neighboring
cells. In light of the lack of astrocytes in current in vitro culture protocols, it is unsurprising that they
have roundly failed to predict the efficacy of new radiosensitizer drugs in human patients, in whom
astrocytes are likely exert radio-protective effects.
Neurons interact with one another through the secretion of neurotransmitters and other factors
from the synaptic cleft. Though the bulk of vesicular release occurs in the so-called “active site” of the
synaptic cleft, a certain amount of secreted factors spill over from the cleft [71]. Neurons and astrocytes
express a variety of receptors and pumps to deal with these extra-synaptic molecules and rely on them
for regulation of neuronal activity and astrocyte behavior [72,73]. Evidence is beginning to accrue
demonstrating that these extra-synaptic molecules can influence GBM progression. For example, it was
recently shown that neuroligin 3, secreted from tumor-promixate neurons, augments tumor growth
and creates a positive feedback loop leading to the generation of tumor-derived neuroligin-3 [74,75].
In addition, tumor cells are known to secrete glutamate in order to further activate neuronal activity,
which can in turn promote their growth [76,77]. A variety of other neurotransmitters have been
suggested as potential players in GBM development, including the monoamines [78]. Again, we
suspect that the lack of neurons and the molecules they contribute to the tumor microenvironment
helps explain the lack of connection between in vitro drug screens and clinical effect.
Endothelial cells from tumor-associated blood vessels also exhibit bidirectional communication
with tumor cells. As previously mentioned, GSC preferentially occupy the perivascular niche,
which contains factors that promote their stem-like phenotype and may also enhance resistance [50].
Furthermore, endothelial cells are known to express membrane bound proteins that enable GBM cells
to invade the surrounding brain parenchyma along blood vessels [79]. Conversely, GBM cells express
high levels of vascular endothelial growth factor (VEGF), which promotes the formation of new blood
vessels [80–82]. Clearly, endothelial cells exercise influence on tumors via secreted factors and contact,
as well as through their influence on the availability of oxygen and nutrients. The lack of endothelial
cells in current in vitro models of GBM therefore limits their utility. For example, GBM cells have been
shown to secrete VEGF following radiation [83]; in a dish that does not contain endothelial cells, any
radio-protective aspect of the subsequent tumor-endothelial interaction is not accounted for, likely
contributing to false positive for new drugs.
Microglia, the brain’s resident macrophage cells, participate in a variety of processes related
to tumor growth. It has been known for almost 100 years that microglia infiltrate throughout
GBM [84]. Recent work has highlighted that these cells actively promote glioma invasion through a
variety of mechanisms, including activation of matrix metalloproteases (MMPs) [85] and secretion of
transforming growth factor-β [86,87] and EGF secretion [88] and through synergistic GBM-derived
colony-stimulating factor-1 (CSF-1). Other groups have also shown that activation of microglia by
tumor cells leads to secretion of factors that promote GBM progression [89]. Indeed, blockade of CSF-1R
on macrophages is sufficient to reduce tumor growth and increase survival in mouse models [90].
These studies show the great influence of tumor associated microglia on tumor progression and
invasion. The fact that microglia—like all the other mentioned non-tumor cells—are excluded from
current culture systems means that in vitro experiments fail to account for an important set of variables
that impinge upon GBM biology.
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2.3.5. Dynamic Surroundings
All of the factors limiting the efficacy of current culture systems share a common element: they
are dynamic. Brain circuits are constantly changing in response to the demands of the environment
and during the processes of cognition. The release of secreted factors like neurotransmitters and
neurotrophic factors into the tumor microenvironment will therefore be constantly changing. Tumor
monocultures, even with the best-intentioned additives, simply cannot match the second by second
variation that occurs in human brain tissue. Take, for example, the way in which growth factors are
added to tissue culture experiments. At the time of seeding cells, high levels of EGF and bFGF are
usually added to the media, a sort of “bolus injection” of growth factor, which is then slowly utilized
or degraded. In contrast, a developing tumor in the cortex will be constantly exposed to different
growth factors and secreted molecules. The dynamic nature of the brain microenvironment cries out
for novel culture techniques and devices to increase the quality and relevance of GBM research.
3. Novel Strategies for GBM Cell Culture
The studies highlighted thus far provide a multitude of reasons to doubt the efficacy of current
culture systems. However, they also indicate specific variables in the design of in vitro practices that
could be manipulated and optimized to develop better mechanisms for investigating radiosensitizing
compounds in GBM. While the sheer multitude of variables is intimidating, a variety of groups have
responded to these challenges with innovative and creative solutions. Table 1 summarizes the exciting
new advances in GBM culture systems, their advantages, and some remaining challenges.
3.1. Suspension-Based Culture Models: Neurospheres and Organotypic Glioma Spheroids
Growing GBM cells in suspension as neurospheres, typically in the presence of EGF, has gained
some traction in recent years [91]. This technique has three distinct advantages. First, it allows
tumor cells to grow in three dimensions, meaning that, other than the outermost layer of cells, they
will be contacting neighbors on all sides, as in actual tumors. Second, evidence suggests that these
neurospheres better preserve the gene expression profile and genetic status of the patient tumors
from which they were derived [11]. Third, in single-cell / cell limiting dilution assays, cells that have
the ability to grow spheres indicates that the GBM cells are maintaining the ability to initiate tumor
formation. Therefore, neurospheres can serve as a useful system for analyzing compounds capable of
limiting tumor growth.
Neurospheres, however, are still a somewhat limited system, because they fail to account for
many of the microenvironmental factors discussed, many of which are known to influence the sphere
forming capacity of GBM cells. Further, suspension culture still introduces the variable of selection
to the generation of patient derived cultures. The conditions encountered in vitro will not match
those of the tumor milieu, and may artificially promote the survival and sphere forming capacity
of certain subpopulations. It has been shown, for example, that GSCs from the edge of tumors are
often highly proliferative, while GSCs from the necrotic core are more quiescent [102]. It is likely
that certain GSCs will outperform others in sphere cultures, biasing any further experiments. Finally,
in our own observations, molecular targeted therapies that have failed to exhibit therapeutic efficacy
in GBM clinical trials such as erlotinib and the anti-diabetic biguanide phenformin exhibit cytotoxic
activity in neurosphere formation assays compared to other in vitro models (Figure 2), suggesting that
anti-glioma compounds identified with this system might not translate in the clinic.
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Table 1. Summary of new in vitro GBM modeling systems.
Novel System Summary Pros Cons Key References
Matrigel Plugs Tumor cells are grow embeddedin a 3D matrigel
Allow cells to grow in 3D
Better approximation of the stiffness of the brain ECM
ECM-derived growth factors better mirror how GFs are
available to the tumor
Mono-culture
Sarcoma ECM is not equivalent to the brain ECM (elevated
collagen and laminin)
[15]
Neurospheres
Cells are grown in suspension,
often in neural stem cell
promoting media
Allow cells to grow in 3D
Ensure that cells examined are tumorigenic, likely the key
target for anti-glioma therapy
Mono-culture [91]
Organotypic glioma spheroids Cells from patient resections,grown in 3D cultures
Multiple cells types (including macrophages and endothelial
cells)
Maintenance of genetic hierarchy within tumor cells
Low throughput
££ [92–95]
3D Scaffolds Cells grow in a matrix, allowingfor 3D cell interactions
Allow cells to grow in 3D
Easily scaled to high-throughput drug screening
Can include brain-ECM specific components
Better recapitulation of gene expression and invasion
Mono-culture
Oxygen and nutrient availability is consistent across the
entire population
££
[18]
Microfluidic Systems
Cells are grown in hydrogel
tubes, which are filled with
circulating media
Time-dependent exposure to nutrients/more dynamic
micronvironment
Allow for the generation of many GSCs from a small initial
sample
Mono-culture
££ [96]
Brain Slices Tumor cells are implanted intomouse brains
Expose tumor to all the neighboring non-tumor cells
Great for examining invasion in the presence of white matter
and secreted factors
Implantation is always problematic
Mouse host with human cells
Lack of circulation
[97–99]
Mini-brains (transduced)
Cerebral organoids are
genetically modified to generate
tumors
Expose tumor to all the neighboring non-tumor cells
Real-time live cell imaging compatible
Allow for examination of tumor initiation and early progression
££
Time requirements
Lack of vessel formation/endothelial cells
Currently lack microglia
Genetic engerieed tumors inherently involve selecting a
driving mutation
Not clear which cell type is being transduced during
electroporation
Still rely on matrigel seed
[100]
Mini-brains (implanted)
Cerebral organoids, once
established, have patient
derived cell injected into the
cortex
High potential for personalization and precision medicine
Human to human graft
££
Time requirements
Lack of vessel formation/endothelial cells
Currently lack microglia
Still rely on matrigel seed
[100,101]
Tumor Organoids
Tumor cells are used as the
starting point for generation of
a “cerebral” organoid
Maintain nutrient and oxygen gradients
Maintain regional intratumoral heterogeneity
Appear to promote preservation of cellular phenotype
Mono-culture
££
Time requirements
Still rely on matrigel seed
[102]
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Figure 2. Comparison of erlotinib and phenformin activity on three different cell culture systems.
(A) Schematic representation (upper panels) and 3D reconstructions of immunofluorescent images
(lower panels) of cells stained for F-actin (red) and nuclei (DAPI, blue) of three cell culture systems:
2D growth on plastic plates (left images, 63× magnification); 3D scaffold growth using 3D-Alvetex
system (middle images 63× magnification); and 3D neurospheres (right images, 63× magnification,
zoom 2×). 2D plastic and 3D scaffolds were previously coated with diluted Matrigel as described in
section Matrigel-coating for 2D growth. (B) Bar charts representing surviving fraction of cells relative
to control grown on different culture systems. G7 and E2 patient-derived GBM cell lines treated with
vehicle (DMSO, control), phenformin (10 µM), or erlotinib (1 µM). Drug-treated cells were normalised
to vehicle (mean ± SD, of three independent experiments). * p < 0.05, relative to DMSO control of their
respective culture system.
In addition to 3D spheroids containing only GBM cells, organotypic spheroids derived from
biopsies and comprising multiple cell types offer an alternative strategy for preclinical tumor modeling.
Developed initially in 1990, these spheroids are generated directly from tissue taken from patients
during biopsies or resections. They maintain several key aspects of the tumor microenvironment,
including intact blood vessels, tumor-associated extracellular matrix, and macrophages [92] and have
been reported to preserve the genomic characteristics of the original tumours [93]. In light of the
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previously discussed importance of the tumor microenvironment, and the non-malignant cells within
it, these spheroids have advantages as preclinical models for therapy development. For example,
organotypic spheroids have been utilized to study the effect of radiotherapy on GBM [103], including
the role of hypoxia in radioresistance [104]. Recent work has continued to highlight their potential for
GBM drug discovery, with a Dutch group demonstrating that 3D spheroids more accurately predict
the efficacy of radiosensitizers than conventional models, and have superior modeling qualities for
investigation of combination therapies [94].
New techniques for the establishment of organotypic spheroids continue to expand, including
the use of ultrasonic aspiration during tumor resection; spheroids derived in this manner maintained
expression of several glioma stem cell markers known to drive aggressive recurrence [95].
The main limitations of these organotypic spheroids are the high cost of establishment and
maintenance and their lack of suitability for high-throughput screening approaches [105]. Because
they rely on rapid utilization of freshly-isolated tumor samples, they are time and cost intensive. These
constraints indicate that organotypic spheroids should perhaps be utilized further along the drug
discovery process as a critical test to determine whether compounds identified by less biologically
relevant, high throughput assays should progress to in vivo evaluation and eventual clinical testing.
3.2. Hydrogels
A variety of hydrogels have been fabricated from a variety of ECM-derived polymers trying to mimic
the biochemical composition of the GBM microenvironment. These include hyaluronic acid [106,107],
chitosan [108], chondroitin sulfate polysaccharides [109], alginates [108] and collagen/gelatin
proteins [106,110]. The use of these hydrogels in GBM has been extensively reviewed by Xiao [111],
so will not be discussed in this review any further. Matrigel is a natural hydrogel of animal origin that
has been extensively used in the GBM field both as a coating-material or as a 3D growth system and
will be discussed further in the sections below.
3.3. Matrigel-Coating for 2D Growth
One of major changes in cell culture for GBM has been the addition of different coatings for plastic
flasks. In theory, these coatings limit the effects of stiff plastic surfaces on tumor cells, as well as allowing
them to occupy an environment with interactions on multiple sides. Matrigel is one of the most
prevalent coating materials for GBM cells. Derived from the extracellular matrix of mouse sacroma
tumors, Matrigel contains a mix of collagen, laminin, and ECM-associated growth factors [112].
One shortcoming of Matrigel coating is the fact that it is derived from sarcoma tumors and
predominately comprised of collagen and laminin. As discussed above, the ECM surrounding GBM
tumors bears little similarity to the ECM of other tumor types. While better than simply growing
brain tumor cells directly on plastic, the composition of Matrigel introduces a variety of variables that
may skew the results of in vitro experiments. Nevertheless, as described above, GSC preferentially
occupy the perivascular niche. Since laminin is one of the main constituents of blood vessels’ walls,
supporting the use of Matrigel-coated plastics for the growth of GSCs.
Another limitation of Matrigel is poor quality control. Because it is extracted from mouse tumors,
it is impossible to ensure that each batch contains equal amounts of the various components. This
fact introduces a major variable across experiments, as one flask may have more growth factor than
another. While imperfect, Matrigel, both for flask coating and as a 3D substrate, remains a key tool
in the current in vitro toolkit, because of its ease of use and the fact it better accounts for the tumor
microenvironment than plastic flasks alone.
3.4. Matrigel Plugs for 3D Growth
Cells growing in 3D laminin and collagen rich gel were more resistant to radiation and
recapitulated the DNA-damage response of xenograft tumors. Mechanistic investigation revealed
that a large portion of this enhanced radioresistance relied on changes in chromatin structure [15].
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As chromatin structure has been indicated as a player in how GSCs overcome therapy [113], this culture
system has great potential as a tool for developing clinically effective radiosensitizers in carcinoma
models. In glioblastoma, GSCs grown in Matrigel plugs display an elongated fibroblastic morphology
and fail to recapitulate key GBM characteristics such as invasion [18] (and personal communication
Dr. Joanna Birch). Extensive analysis of the morphology and radiation responses of these cells in our
laboratory has indicated this tool is not suitable for GBM models.
3.5. 3D Scaffolds
Another strategy for improving the efficacy of in vitro models of GBM is the use of
three-dimensional (3D) scaffolds. A recent report showed that Matrigel-coated 3D polystyrene
scaffolds (3D-Alvetex; Figure 2) provided an excellent mechanism for predicting the clinical efficacy
of anti-GBM modalities; screens using these 3D cultures correcting identified temozolomide and
bevacuzimab as capable of limiting GBM growth, while indicating no efficacy of erlotinib, both
alone and combined with radiation [18]. GSCs grown in these 3D scaffolds exhibited morphologies
present in human tumours such as microtubes [114] and produced invasion patterns more similar to
GBM tumors in brain slices (Joanna Birch, personal communication). This model has two limitations.
First, substrate stiffness which can infuence phenotype, proliferation and differentiation in some cell
types [115]. These effects have been shown to be overriden by increasing seeding density in a human
mesenchymal stem cell 3D model using poly-acrylamide gels [116], suggesting that intercellular
distance regulates cell morphology and fate. Second, cell retrieval from polystyrene scaffolds is
never 100% effective, and cells retrieved may artificially select subpopulations with more invasive
capacity or those that are more loosely attached to the matrix, making this system inadequate for
cell maintenance or for experiments requiring cell suspensions such as fluorescence activated cell
sorting (FACS). Another group recently demonstrated that a 3D collagen scaffold enables growth of
GBM cells that better recapitulate the gene expression of GSCs, as well as more faithfully reflect how
tumor cells respond to alkylating chemotherapy [117]. Furthermore, a group from the University
of Alabama is currently developing a microtumor 3D culture system for patient derveid samples,
using a humanized matrigel alternative. Their research suggests that this model more effectively
predicts kinase activity and signaling pathway status than 2D models [118]. As with matrigel, the ECM
engulfing GBM tumors contain little collagen, rendering this system as a suboptimal representation of
GBM tumor microenvironment. More experiments are needed to further validate if these models can
predict translational activity in GBM.
While these scaffolds are still purified monocultures of GBM cells, they appear to have a great
advantage over 2D flask cultures in terms of generating cultures that reflect drug sensitivities of actual
patient tumors. They also have a great advantage of some of the other new systems discussed here,
in that 3D scaffolds appear to be easily and relatively cheaply applied to high-throughput systems,
including 96 well plates (e.g., Alvetex). These scaffolds allow researchers to continue to use the same
basic culture techniques, while improving the efficacy and accuracy of screens. This ease of use may
mean that 3D cultures represent an ideal early stage or massive compound library screening tool,
results of which are then confirmed in a more complex model.
In addition to 3D scaffolds made of collagen and polysterene, a growing body of work on
biomaterials may provide new systems for culturing GBM cells (reviewed [119]). As discussed above,
a major limitation of current culture systems is that they do not create a surface similar to the actual
brain ECM. Matrigel, for example, is largely made up of laminin and collagen, two proteins in low
concentration in the brain ECM. In response to this discrepancy, new biomaterial scaffolds are under
development. Beginning in 2011, the Kumar group developed a 3D scaffold composed on hyaluronic
acid (a major component of the brain and tumor ECM) and hydrogel; this scaffold produced invasion
patterns more similar to GBM tumors in brain slices than on collagen based scaffolds [120]. More recent
work has established that hyaluronic acid rich hydrogel matrices allow for culturing of patient-derived
GBM cells from human patients. Cells growing on this matrix exhibited morphology and drug
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sensitivity more similar to actual tumor samples than cells growing in 2D [109,121]. Recently, these
hyaluronic acid scaffolds were engineered to include several key matrix metal proteases from the
brain ECM. This system also generated 3D cultures of GBM with phenotypes more reflective of actual
tumors [122]. Other groups have generated matrices using hyaluronic acid and chitosan (another
key brain ECM component); these matrices more effectively maintain tumor growth patterns and
expression of key GSC markers than 2D cultures [108]. These scaffolds have enabled researchers
to more fully delineate the effect of the brain ECM on GBM behavior, including invasion [123,124],
growth [125], and sensitivity to novel therapies [126,127].
3.6. Microfluidic Systems
In order to address the problem of growing cells in static media, researchers have explored the
use of microfluidic systems, in which liquid media can be continually passed through growing cells.
One exciting example of the use of fluidic chambers in GBM is the generation of glioma cultures for
drug discovery came from a recent report, in which GBM primary cells were cultured in a network of
hydrogel tubes with circulating media [96]. Cells were pumped into these tubes in a solution containing
several brain specific ECM components, including hyalurlonic acid. As the tumor cells grew, they
formed small spheres along the edges of the tubes; with longer incubation, they generated continuous
strands of cells, marked by high expression of GSC markers. Another novel microfluidic-based
system is currently in development at the University of Houston. Termed the “brain cancer chip”,
it enables 3D culture of freshly dissociated tumor cells from surgical resection or biopsy specimens.
Improved chip design ensures that drugs do not leach between wells, enabling effective drug screening
applications [128].
The advantage of these systems appears to be based on the ability to expose GBM cells to
CNS-specific ECM molecules and generate high numbers of GSCs. Further, the ability to control the
microenvironment surrounding the developing cells via alterations in the composition of the feeding
media reservoir could be leveraged to create more dynamic and realistic exposures to key growth
factors and other variables, such as acidity. The limitations of this system are two fold. First and
foremost, it remains a monoculture, meaning that it fails to account for non-tumor cell contributions
to GBM growth. Secondly, it is unclear how this system can be applied to assays and drug screens.
The authors themselves seem to suggest that the best use of this system would be to generate high
yields of representative GSCs that will then be used for some other drug screening process.
3.7. Brain Slices
Another innovative solution for assaying GBM behavior in vitro involves borrowing a technique
from the field of neuroscience. Coronal organotypic slices have been a mainstay of electrophysiology
studies for years [129]. Briefly, the process involves sacrificing mice and then removing their brains.
After dissecting away the olfactory bulb and the cerebellum, brains are sliced on the coronal plane,
usual to a width of 200 µM. They can then be kept alive in media for up to several weeks. Groups will
then implant GBM cells via nano-injector. This system enables live cell imaging, and has already been
used to investigate tumor cell invasion processes [97] and the role of microglia in tumor growth [98].
Another group has used a similar system to show that GBM cells engraft more effectively and grow
more quickly in different areas of the brain, indicating microenvironmental forces are key factors
governing tumor growth [99].
The key advantage of this method is that it enables experimenters to test hypotheses on tumors
that are surrounded by the same populations of cells they would encounter in the human brain. As the
mentioned study showed, regional differences in the microenvironment are maintained in coronal
slices. Another key feature of these slices, also demonstrated by the referenced studies, is they maintain
functional microglial populations, allowing for investigation of the role of these resident macrophages
in tumor development [97,98]. There are, however, still limitations to this system, most notably the
disruption of blood-flow related factors and the fact that the brain slice and tumor engraftment are
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bathed in nutrient and oxygen rich media. Despite these issues, organotypic cultures appear to be
an excellent tool for investigating mechanisms of microenvironmenal interactions as part of the drug
development process.
3.8. Mini-Brains
An exciting and emerging platform for modeling glioblastoma tumor in vitro utilizes cerebral
organoids—so called “Mini-Brains”. The process of generating a cerebral organoid begins with
pluripotent stem cells, which are then slowly grown and differentiated using sequential changes in
media and additives. In the final stages, organoids are grown in rotating bioreactors. These mini-brains
contain morphologically accurate and functionally mature populations of all brain cell types; they
also recapitulate regional differences in the brain [101] (reviewed [130,131]). These brain organoids
allow for the investigation of tissue dynamics in real time, including microscope imaging in live cells.
Since their creation in 2013, mini-brain modeling has continued to improve, including the generation
of microfluidic chip platforms to create perfusion within the organoid-containing dish [132].
This technology has been used to investigate a variety of neurological deficits and is beginning to
be applied to GBM. Ogawa and colleagues recently developed two distinct mechanisms for utilizing
mini-brains to model GBM development—genetically engineered tumors and orthotopic implantation
of patient derived cells [100]. In the first instance, they utilized a duel construct electroporation strategy,
in which one construct relied on CRISPR-Cas9 technology altered the fourth exon of TP53 to generate
a truncated and non-functional p53 protein. The second construct introduced an oncogenic HRas
virus. Co-electroporation of these constructs into the cortical region of mature cerebral organoids led
to the development of tumors that recapitulated many of the key features of GBM, including invasive
potential and the presence of GSCs. Their second strategy relied on microinjection of patient-derived
cells. Two lines were implanted, one which forms tumors in mouse models and one that fails to
engraft in mouse cortical tissue; these features were maintained when cells were injected into cerebral
organoids. Other groups are currently working to develop similar GBM models, including Howard
Fine, who was just awarded NIH funding for the expressed purpose of utilizing cerebral organoids for
precision medicine for GBM.
Clearly, mini-brains represent an exciting development in modeling brain cancer. They are not,
however, without their remaining challenging. Most pressing in our minds, they lack both endothelial
cells and microglia. As discussed, endothelial cells and the blood vessels they form are critical players
in GBM progression and therapy resistance, as well as provide a key GSC niche. Experiments in
cerebral organoids therefore still fail to account for the role of vasculature and the communication
between tumors and endothelial cells. In addition, microglia help regulate tumor growth and invasion.
The lack of these cells, as well as any peripheral immune cells, in mini-brains may limit their utility for
examining certain therapies, especially immunotherapies. It has been suggested that microglia, derived
from pluripotent stem cells separately differentiated, could be added to the mini-brain production
process [133], thereby bypassing this issue. Further research will determine how to overcome these
challenges. The fact that cerebral organoids can recapitulate the neuronal and astrocytic portions of
cortical tissue means they have great potential as in vitro drug-development and drug screening tools
for brain cancer.
3.9. Tumor Organoids
Building on this exciting work in growing cerebral organoids, other groups have utilized similar
techniques in an attempt to develop tumor organoids. Briefly, initial tumor cells (patient derived,
patient derived metastases, or genetically engineered) are seeded on small Matrigel pellets. After
a few days, they are transferred to a rotation bioreactor, similar to those used to generate cerebral
organoids [102]. This group found that tumor organoids maintain oxygen gradients across the tumor,
as well as produce a tumor complete with different subpopulations and neo-GSC satellite areas.
Radiosensitivity assays also demonstrated that these cultures faithfully mirror the differences in
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different tumor subpopulations, with differentiated GBM cells dying in response to radiation while
neighboring GSCs were resistant. These aspects of the model address several of the issues plaguing
simpler in vitro models, including reliably creating a heterogeneous tumor, complete with regional
differences in microenvironment and subpopulations differences. While these organoids are still a
mono-culture system, and therefore do not account for the influence of non-tumor cells, they have
great potential for drug screening assays, especially radiosensitizers.
4. Conclusions, Caveats, and Future Directions
The process of in vitro culturing of GBM cells is fraught with challenges. However, as this
review shows, innovative and creative solutions are under development to overcome these difficulties.
Through the use of new technologies in bioengineering and nano-scale printing, labs are developing
new models that better recapitulate the complexity of GBM tumors and their microenvironment.
Through continued collaborations across disciplines—from biomaterials experts, to tumor biologists,
neuroscientists, and radiation oncologists—these technologies may well unearth new options for GBM
patients in desperate need of better therapies.
There remain several potential difficulties with these technologies. First and foremost, none
of the discussed culture systems enables researchers to determine how candidate compounds will
interact with the blood-brain-barrier. Poor penetrance has been a key factor in the downfall of many
promising anti-glioma agents [134,135]. If these new in vitro protocols are to be applied to compound
screening and drug development, they will still require groups to investigate BBB permeability after
identification. Relatedly, the lack of functional blood vessels means these systems still have a blind spot
in terms of how GBM tumors interact with endothelial cells. A large amount of evidence indicating
that interactions between these cells and GBM tumors, especially regarding neo-vascularization and
GSC niche, are critical to tumor progression and resistance to radiotherapy.
Another key challenge in optimizing preclinical models of GBM is ensuring relevance to clinical
treatments. Since brain tumor therapy relies on the combination of radiation and drug treatment, assay
design for in vitro drug investigations must faithfully account for the timing and sequence of therapy
in actual patients. This point has been persuasively argued by Stone and colleagues [136]. Considering
applicability to clinical use from the beginning, coupled with these exciting new models, will ensure
that drug discovery and development for GBM is built on a solid foundation.
None of these remaining challenges, however, should dissuade the brain cancer research
community from forging ahead in utilizing and improving these new systems. As mentioned,
all of them represent substantial improvements over traditional flask culturing. Rather, we hope
this discussion of the persistent challenges facing in vitro will inform discussion about the next
steps forward.
We suspect that, like many developments in the cancer researchers toolkit, a combination of
different systems will be key. As mentioned, certain systems can be more readily adopted by many
groups, as well as scaled up for high-throughput drug screening. We predict that tools like 3D scaffolds
may be applied to large compound library screens, after which promising candidates are screened
using a more complex culture system, such as cerebral organoids. In contrast, researchers investigating
more mechanistic insights may find other tools most useful, such as organotypic brain slices for live
cell imaging investigating GBM’s marked invasion capacity. These novel culture systems have and
will continue to advance our ability to better understand this immensely complicated tumor.
Looking to the future, the applications of the burgeoning field of 3D culture are vast. One exciting
prospect of these novel culture systems is their potential use in personalized medicine. By using patient
cells collected during primary tumor resection as the basis for generation of tumor organoids or for
implantation into cerebral organoids, a multitude of compounds could be screened for each individual
patient. Based on existing studies, there is a high probability that these implants or organoids will
maintain the intratumoral diversity of patient tumors, thereby creating an opportunity to screen drugs
and personalize treatment for each person.
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In summary, current GBM culturing systems create vastly over-simplified tumor models. This
imperfect models fail to properly predict clinical efficacy of new compounds, leading to wasteful and
ineffective trials. Several factors have been proposed to underlie the mismatch between efficacy in
the flaks and in actual patients, including artificial selection pressures, the lack of non-tumor cells in
culture, and unnatural extracellular matrices and nutrient availability. In response, a variety of new
and innovative culture systems are under-development to provide a new system for testing potential
anti-glioma therapies. From 3D scaffolds to organoid generation, novel models better recapitulate
tumor dynamics and microenvironmental interactions, enabling more accurate understanding of GBM
biology. The field of neuro-oncology seems poised to experience a revolution in in vitro drug screening
and development, building on these exciting developments to hopefully provide new therapeutic
strategies to patients in need.
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